ArticleFrontiers in endocrinology2025
Transcriptome analysis and RT-qPCR validation of mitophagy-related key genes in the progression of diabetic retinopathy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exercise as a Programmable Regulator of Mitophagy Sensitivity in Aging Muscle and Age-Related Disease.IUBMB life · 2026Review
- Remodeling of the mitochondrial quality control network: natural products intervening in diabetic retinopathy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR), a prevalent microvascular complication of diabetes mellitus (DM), likely involves mitophagy in its progression. However, the exact mechanisms remain poorly understood. Methods: This study analyzed DR datasets GSE189005 and GSE221521 from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs 1) between patients with DR and controls were identified from GSE189005. Simultaneously, mitophagy-related genes (MRGs) were analyzed to determine DEGs 2. The datasets were integrated to obtain differentially expressed MRGs. A machine learning-based approach was used to identify key candidate genes, followed by expression validation. Additionally, a nomogram was constructed for DR risk prediction; correlation analysis was performed between key genes and immune cells; RT-qPCR analysis was conducted to verify gene expression. Results: Integration of datasets revealed 13 differentially expressed MRGs. Five key candidate genes were identified via machine learning, and expression validation confirmed the differential expression of SLC1A5 and RPS21 in DR. The nomogram incorporating these two genes showed high predictive accuracy for DR risk. SLC1A5 was strongly positively correlated with CD56 bright NK cells (r = 0.82) and negatively correlated with CD56 dim NK cells (r = -0.80). RPS21 exhibited the strongest positive correlation with CD56 dim NK cells (r = 0.77) and the strongest negative correlation with CD56 bright NK cells (r = -0.75). RT-qPCR analysis indicated significant upregulation of SLC1A5 and downregulation of RPS21 in DR samples. Conclusions: This study suggests that SLC1A5 and RPS21 are involved in DR progression, offering potential therapeutic targets. However, further experimental validation is necessary to confirm their functional roles and clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.